Feb 27, 2026 8:30 am EST RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
Feb 26, 2026 8:30 am EST RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
Feb 5, 2026 8:30 am EST RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Feb 4, 2026 8:30 am EST RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Jan 28, 2026 8:30 am EST RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
Jan 20, 2026 8:30 am EST RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
Jan 8, 2026 8:30 am EST RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
Dec 11, 2025 8:30 am EST RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
